In Young Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
In Young Kang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Dae Won Jun
Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea
1 shared publication Hyun Sung Kim
Department of Pathology Hanyang University School of Medicine Seoul 04763 Republic of Korea
1 shared publication- Hyunbeom Lee
Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul, Republic of Korea.
1 shared publication - Jeesoo Kim
Center for Advanced Biomolecular Recognition Korea Institute of Science and Technology Seoul 02792 Republic of Korea
1 shared publication - Jinyoung Park
Molecular Recognition Research Center, Korea Institute of Science and Technology, Seoul 02792, Korea
1 shared publication - Joonseok Lee
Department of Chemistry Hanyang University Seoul Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 4 October 2025
- Published by Wiley in Advanced Materials
- Vol. 38 (7) , e06373
LDI, A Lipid Droplet Inhibitor, Disrupts Lipid Accumulation and Modulates Hepatic Lipid Profiles in Fatty Liver
Excessive lipid droplet accumulation in hepatocytes drives the progression of metabolic dysfunction‐associated steatotic liver disease (MASLD), often leading to inflammation and fibrosis. As obesity and metabolic syndrome rise, MASLD has become a global concern, spurring research into effective treatments. Here, the design of a Lipid droplet inhibitor (LDI) is presented, incorporating porous silica nanostructures along with PKCα C1A and Candida Rugosa lipase, aimed at directly degrading lipid droplets. Through its dual‐functional design, this nanostructure captures diacylglycerol using PKCα C1A while hydrolyzing triacylglycerol into smaller molecular fragments via the lipase. Notably, the amphiphilic biomolecules in LDI facilitate the formation of a Pickering emulsion, ensuring stable localization at the lipid‐water interface for efficient interaction with lipid droplets. LDI reduces lipid droplet formation and triglyceride levels in palmitic acid‐treated HepG2 cells. In a high‐fat diet‐induced MASLD model, it alleviateds liver pathology and, lowered injury scores by up to 84%. Furthermore, lipidomic analysis confirmed that LDI effectively modulated the hepatic lipid profile, suggesting its potential as a nanoplatform for counteracting lipid droplet accumulation.
- 4 October 2025
- Published by Wiley in Advanced Materials
- Vol. 38 (7) , e06373
Open AccessLDI, A Lipid Droplet Inhibitor, Disrupts Lipid Accumulation and Modulates Hepatic Lipid Profiles in Fatty Liver
Excessive lipid droplet accumulation in hepatocytes drives the progression of metabolic dysfunction‐associated steatotic liver disease (MASLD), often leading to inflammation and fibrosis. As obesity and metabolic syndrome rise, MASLD has become a global concern, spurring research into effective treatments. Here, the design of a Lipid droplet inhibitor (LDI) is presented, incorporating porous silica nanostructures along with PKCα C1A and Candida Rugosa lipase, aimed at directly degrading lipid droplets. Through its dual‐functional design, this nanostructure captures diacylglycerol using PKCα C1A while hydrolyzing triacylglycerol into smaller molecular fragments via the lipase. Notably, the amphiphilic biomolecules in LDI facilitate the formation of a Pickering emulsion, ensuring stable localization at the lipid‐water interface for efficient interaction with lipid droplets. LDI reduces lipid droplet formation and triglyceride levels in palmitic acid‐treated HepG2 cells. In a high‐fat diet‐induced MASLD model, it alleviateds liver pathology and, lowered injury scores by up to 84%. Furthermore, lipidomic analysis confirmed that LDI effectively modulated the hepatic lipid profile, suggesting its potential as a nanoplatform for counteracting lipid droplet accumulation.